Development of the PANVAC™-VF vaccine for pancreatic cancer

References

• Buist JB. The life-history of the microorganisms associated with variola and vaccinia. Proc. R. Soc. 13, 603 (1886).
   Google Scholar
• Baxby D. Edward Jenner’s Inquiry; a bicentenary analysis. Vaccine 17(4), 301–307 (1999).
   PubMed Web of Science ®Google Scholar
• Johnson GP, Goebel SJ, Paoletti E. An update on the vaccinia virus genome. Virology 196(2), 381–401 (1993).
   PubMed Web of Science ®Google Scholar
• Gillard S, Spehner D, Drillien R. Mapping of a vaccinia host range sequence by insertion into the viral thymidine kinase gene. J. Virol. 53(1), 316–318 (1985).
   PubMed Web of Science ®Google Scholar
• Edghill-Smith Y, Golding H, Manischewitz J et al. Smallpox vaccine-induced antibodies are necessary and sufficient for protection against monkeypox virus. Nature Med. 11(7), 740–747 (2005).
   PubMed Web of Science ®Google Scholar
• Kennedy JS, Frey SE, Yan L et al. Induction of human T cell-mediated immune responses after primary and secondary smallpox vaccination. J. Infect. Dis. 190(7), 1286–1294 (2004).
   PubMed Web of Science ®Google Scholar
• Paoletti E. Applications of pox virus vectors to vaccination: an update. Proc. Natl Acad. Sci. USA 93(21), 11349–11353 (1996).
   PubMed Web of Science ®Google Scholar
• Breman JG, Arita I, Fenner F. Preventing the return of smallpox. N. Engl. J. Med. 348(5), 463–466 (2003).
   PubMed Web of Science ®Google Scholar
• Carroll MW, Moss B. Poxviruses as expression vectors. Curr. Opin. Biotechnol. 8(5), 573–577 (1997).
   PubMed Web of Science ®Google Scholar
• Smith GL. Vaccinia virus vectors for gene expression. Curr. Opin. Biotechnol. 2(5), 713–717 (1991).
   PubMedGoogle Scholar
• Essajee S, Kaufman HL. Poxvirus vaccines for cancer and HIV therapy. Expert Opin. Biol. Ther. 4(4), 575–588 (2004).
   PubMed Web of Science ®Google Scholar
• Starnes CO. Coley’s toxins in perspective. Nature 357(6373), 11–12 (1992).
   PubMed Web of Science ®Google Scholar
• Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD. Cancer immunoediting: from immunosurveillance to tumor escape. Nature Immunol. 3(11), 991–998 (2002).
   PubMed Web of Science ®Google Scholar
• Ostrand-Rosenberg S. Animal models of tumor immunity, immunotherapy and cancer vaccines. Curr. Opin. Immunol. 16(2), 143–150 (2004).
   PubMed Web of Science ®Google Scholar
• Stevenson FK. Update on cancer vaccines. Curr. Opin. Oncol. 17(6), 573–577 (2005).
   PubMed Web of Science ®Google Scholar
• Panicali D, Davis SW, Weinberg RL, Paoletti E. Construction of live vaccines by using genetically engineered poxviruses: biological activity of recombinant vaccinia virus expressing influenza virus hemagglutinin. Proc. Natl Acad. Sci. USA 80(17),5364–5368 (1983).
   PubMed Web of Science ®Google Scholar
• Gold P, Freedman SO. Demonstration of tumor specific antigen in human colonic carcinomata by immunological tolerance and absorption techniques. J. Exp. Med. 121, 439 (1965).
   PubMed Web of Science ®Google Scholar
• Robbins PF, Eggensperger D, Qi CF, Schlom J. Definition of the expression of the human carcinoembryonic antigen and non-specific cross-reacting antigen in human breast and lung carcinomas. Int. J. Cancer 53(6), 892–897 (1993).
   PubMed Web of Science ®Google Scholar
• Tendler A, Kaufman HL, Kadish AS. Increased carcinoembryonic antigen expression in cervical intraepithelial neoplasia grade 3 and in cervical squamous cell carcinoma. Hum. Pathol. 31(11), 1357–1362 (2000).
   PubMed Web of Science ®Google Scholar
• Benchimol S, Fuks A, Jothy S, Beauchemin N, Shirota K, Stanners CP. Carcinoembryonic antigen, a human tumor marker, functions as an intercellular adhesion molecule. Cell 57, 327–334 (1989).
   PubMed Web of Science ®Google Scholar
• Oikawa S, Nakazato H, Kosaki G. Primary structure of human carcinoembryonic antigen (CEA) deduced from cDNA sequence. Biochem. Biophys. Res. Commun. 142(2), 511–518 (1987).
   PubMed Web of Science ®Google Scholar
• Siler K, Eggensperger D, Hand PH et al. Therapeutic efficacy of a high-affinity anticarcinoembryonic antigen monoclonal antibody (COL-1). Biotechnol. Ther. 4(3–4), 163–181 (1993).
   PubMedGoogle Scholar
• Kaufman H, Schlom J, Kantor J. A recombinant vaccinia virus expressing human carcinoembryonic antigen (CEA). Int. J. Cancer 48(6), 900–907 (1991).
   PubMed Web of Science ®Google Scholar
• Kantor J, Irvine K, Abrams S, Kaufman H, DiPietro J, Schlom J. Antitumor activity and immune responses induced by a recombinant carcinoembryonic antigen-vaccinia virus vaccine. J. Natl Cancer Inst. 84(14), 1084–1091 (1992).
   PubMed Web of Science ®Google Scholar
• Kantor J, Irvine K, Abrams S et al. Immunogenicity and safety of a recombinant vaccinia virus vaccine expressing the carcinoembryonic antigen gene in a nonhuman primate. Cancer Res. 52(24), 6917–6925 (1992).
   PubMed Web of Science ®Google Scholar
• Kaufman H, DiVito J Jr, Horig H. Immunotherapy for pancreatic cancer: current concepts. Hematol. Oncol. Clin. North Am. 16(1), 159–197 (2002).
   PubMed Web of Science ®Google Scholar
• Taylor-Papadimitriou J, Burchell JM, Plunkett T et al. MUC1 and the immunobiology of cancer. J. Mammary Gland Biol. Neoplasia. 7(2), 209–221 (2002).
   PubMed Web of Science ®Google Scholar
• Hiltbold EM, Alter MD, Ciborowski P, Finn OJ. Presentation of MUC1 tumor antigen by class I MHC and CTL function correlate with the glycosylation state of the protein taken up by dendritic cells. Cell Immunol. 194(2), 143–149 (1999).
   PubMed Web of Science ®Google Scholar
• Finn OJ, Jerome KR, Henderson RA et al. MUC-1 epithelial tumor mucin-based immunity and cancer vaccines. Immunol. Rev. 145, 61–89 (1995).
   PubMed Web of Science ®Google Scholar
• Kotera Y, Fontenot JD, Pecher G, Metzgar RS, Finn OJ. Humoral immunity against a tandem repeat epitope of human mucin MUC-1 in sera from breast, pancreatic, and colon cancer patients. Cancer Res. 54(11), 2856–2860 (1994).
   PubMed Web of Science ®Google Scholar
• Graham RA, Burchell JM, Beverley P, Taylor-Papadimitriou J. Intramuscular immunisation with MUC1 cDNA can protect C57 mice challenged with MUC1-expressing syngeneic mouse tumour cells. Int. J. Cancer 65(5), 664–670 (1996).
   PubMed Web of Science ®Google Scholar
• Akagi J, Nakagawa K, Egami H, Ogawa M. Induction of HLA-unrestricted and HLA-class-II-restricted cytotoxic T lymphocytes against MUC-1 from patients with colorectal carcinomas using recombinant MUC-1 vaccinia virus. Cancer Immunol. Immunother. 47(1), 21–31 (1998).
   PubMed Web of Science ®Google Scholar
• Cohen S, Kaufman HL. TG-4010 transgene. Curr. Opin. Investig. Drugs 5(12), 1319–1328 (2004).
   PubMedGoogle Scholar
• Parker KC, Shields M, DiBrino M, Brooks A, Coligan JE. Peptide binding to MHC class I molecules: implications for antigenic peptide prediction. Immunol. Res. 14(1), 34–57 (1995).
   PubMed Web of Science ®Google Scholar
• Germain RN, Margulies DH. The biochemistry and cell biology of antigen processing and presentation. Ann. Rev. Immunol. 11, 403–450 (1993).
   PubMed Web of Science ®Google Scholar
• Collins EJ, Frelinger JA. Altered peptide ligand design: altering immune responses to class I MHC/peptide complexes. Immunol. Rev. 163, 151–160 (1998).
   PubMed Web of Science ®Google Scholar
• Zaremba S, Barzaga E, Zhu M, Soares N, Tsang KY, Schlom J. Identification of an enhancer agonist cytotoxic T lymphocyte peptide from human carcinoembryonic antigen. Cancer Res. 57(20), 4570–4577 (1997).
   PubMed Web of Science ®Google Scholar
• Tsang KY, Palena C, Gulley J, Arlen P, Schlom J. A human cytotoxic T-lymphocyte epitope and its agonist epitope from the nonvariable number of tandem repeat sequence of MUC-1. Clin. Cancer Res. 10(6), 2139–2149 (2004).
   PubMed Web of Science ®Google Scholar
• Chambers CA. The expanding world of co-stimulation: the two-signal model revisited. Trends Immunol. 22(4), 217–223 (2001).
   PubMed Web of Science ®Google Scholar
• Heeg K, Wagner H. Induction of responsiveness in superantigen-induced anergic T cells. Role of ligand density and costimulatory signals. J. Immunol. 155(1), 83–92 (1995).
   PubMed Web of Science ®Google Scholar
• Guelly C, Kupcu Z, Zalusky D, Karner M, Zehetner M, Schweighoffer T. Activation requirements of circulating antigen-specific human CD8(+) memory T cells probed with insect cell-based artificial antigen-presenting cells. Eur. J. Immunol. 32(1), 182–192 (2002).
   PubMed Web of Science ®Google Scholar
• Egen JG, Kuhns MS, Allison JP. CTLA-4: new insights into its biological function and use in tumor immunotherapy. Nature Immunol. 3(7), 611–618 (2002).
   PubMed Web of Science ®Google Scholar
• Evans DE, Weinberg AD. Boosting T cell costimulation in cancer: the possibilities seem endless. Int. Rev. Immunol. 22(2), 173–194 (2003).
   PubMed Web of Science ®Google Scholar
• Hodge JW, McLaughlin JP, Abrams SI, Shupert WL, Schlom J, Kantor JA. Admixture of a recombinant vaccinia virus containing the gene for the costimulatory molecule B7 and a recombinant vaccinia virus containing a tumor-associated antigen gene results in enhanced specific T-cell responses and antitumor immunity. Cancer Res. 55(16), 3598–3603 (1995).
   PubMed Web of Science ®Google Scholar
• Hodge JW, Sabrezevari H, Yafal AG et al. A triad of costimulatory molecules synergize to amplify T-cell activation. Cancer Res. 59(22), 5800–5807 (1999).
   PubMed Web of Science ®Google Scholar
• Grosenbach DW, Barrientos JC, Schlom J, Hodge JW. Synergy of vaccine strategies to amplify antigen-specific immune responses and antitumor effects. Cancer Res. 61(11), 4497–4505 (2001).
   PubMed Web of Science ®Google Scholar
• Yang S, Hodge JW, Grosenbach DW, Schlom J. Vaccines with enhanced costimulation maintain high avidity memory CTL. J. Immunol. 175(6), 3715–3723 (2005).
   PubMed Web of Science ®Google Scholar
• Yang S, Hodge JW, Grosenbach DW, Schlom J. Vaccines with enhanced costimulation maintain high avidity memory CTL. J. Immunol. 175(6), 3715–3723 (2005).
   PubMed Web of Science ®Google Scholar
• McLaughlin JP, Schlom J, Kantor JA, Greiner JW. Improved immunotherapy of a recombinant carcinoembryonic antigen vaccinia vaccine when given in combination with interleukin-2. Cancer Res. 56(10), 2361–2367 (1996).
   PubMed Web of Science ®Google Scholar
• Elkins KL, Ennist DL, Winegar RK, Weir JP. In vivo delivery of interleukin-4 by a recombinant vaccinia virus prevents tumor development in mice. Hum. Gene Ther. 5(7), 809–820 (1994).
   PubMed Web of Science ®Google Scholar
• Kaufman HL, Rao JB, Irvine KR, Bronte V, Rosenberg SA, Restifo NP. Interleukin-10 enhances the therapeutic effectiveness of a recombinant poxvirus-based vaccine in an experimental murine tumor model. J. Immunother. 22(6), 489–496 (1999).
   PubMed Web of Science ®Google Scholar
• Rao JB, Chamberlain RS, Bronte V et al. IL-12 is an effective adjuvant to recombinant vaccinia virus-based tumor vaccines: enhancement by simultaneous B7–1 expression. J. Immunol. 156(9), 3357–3365 (1996).
   PubMed Web of Science ®Google Scholar
• Chatterjee SK, Qin H, Manna S, Tripathi PK. Recombinant vaccinia virus expressing cytokine GM-CSF as tumor vaccine. Anticancer Res. 19(4B), 2869–2873 (1999).
   PubMed Web of Science ®Google Scholar
• Kaufman HL, Flanagan K, Lee CS, Perretta DJ, Horig H. Insertion of interleukin-2 (IL-2) and interleukin-12 (IL-12) genes into vaccinia virus results in effective antitumor responses without toxicity. Vaccine 20(13–14), 1862–1869 (2002).
   PubMed Web of Science ®Google Scholar
• Carroll MW, Overwijk WW, Surman DR, Tsung K, Moss B, Restifo NP. Construction and characterization of a triple-recombinant vaccinia virus encoding B7–1, interleukin-12, and a model tumor antigen. J. Natl Cancer Inst. 90(24), 1881–1887 (1998).
   PubMedGoogle Scholar
• Van Elsas A, Hurwitz AA, Allison JP. Combination immunotherapy of B16 melanoma using anticytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accompanied by autoimmune depigmentation. J. Exp. Med. 190(3), 355–366 (1999).
   PubMed Web of Science ®Google Scholar
• Hurwitz AA, Yu TF, Leach DR, Allison JP. CTLA-4 blockade synergizes with tumor-derived granulocyte-macrophage colony-stimulating factor for treatment of an experimental mammary carcinoma. Proc. Natl Acad. Sci. USA 95(17), 10067–10071 (1998).
   PubMed Web of Science ®Google Scholar
• Dunussi-Joannopoulos K, Weinstein HJ, Arceci RJ, Croop JM. Gene therapy with B7.1 and GM-CSF vaccines in a murine AML model. J. Pediatr. Hematol. Oncol. 19(6), 536–540 (1997).
   PubMed Web of Science ®Google Scholar
• Grosenbach DW, Barrientos JC, Schlom J, Hodge JW. Synergy of vaccine strategies to amplify antigen-specific immune responses and antitumor effects. Cancer Res. 61(11), 4497–4505 (2001).
   PubMed Web of Science ®Google Scholar
• Aarts WM, Schlom J, Hodge JW. Vector-based vaccine/cytokine combination therapy to enhance induction of immune responses to a self-antigen and antitumor activity. Cancer Res. 62(20), 5770–5777 (2002).
   PubMed Web of Science ®Google Scholar
• Viner KM, Isaacs SN. Activity of vaccinia virus-neutralizing antibody in the sera of smallpox vaccinees. Microbes Infect. 7(4), 579–583 (2005).
   PubMed Web of Science ®Google Scholar
• Hodge JW, McLaughlin JP, Kantor JA, Schlom J. Diversified prime and boost protocols using recombinant vaccinia virus and recombinant non-replicating avian pox virus to enhance T-cell immunity and antitumor responses. Vaccine 15(6–7), 759–768 (1997).
   PubMed Web of Science ®Google Scholar
• Eades-Perner AM, van der Putten H, Hirth A et al. Mice transgenic for the human carcinoembryonic antigen gene maintain its spatiotemporal expression pattern. Cancer Res. 54, 4169–4176 (1994).
   PubMed Web of Science ®Google Scholar
• Aarts WM, SchlomJ, Hodge JW. Vector-based vaccine/cytokine combination therapy to enhance induction of immune responses to a self-antigen and antitumor activity. Cancer Res. 62(20), 5770–5777 (2002).
   PubMed Web of Science ®Google Scholar
• McAneny D, Ryan C, Beazley R, Kaufman H. Results of a Phase I clinical trial using a recombinant vaccinia-carcinoembryonic antigen (CEA) vaccine in patients with advanced colorectal cancer. Ann. Surg. Oncol. 3(5), 495–500 (1996).
   PubMed Web of Science ®Google Scholar
• Anthony DD, Lehmann PV. T-cell epitope mapping using ELISPOT approach. Methods 29(3), 260–269 (2003).
   Google Scholar
• Arlen P, Tsang KY, Marshall JL et al. The use of a rapid ELISPOT assay to analyze peptide-specific immune responses in carcinoma patients to peptide vs. recombinant poxvirus vaccines. Cancer Immunol. Immunother. 49(10), 517–529 (2000).
   PubMed Web of Science ®Google Scholar
• Marshall JL, Hawkins MJ, Tsang KY et al. Phase I study in cancer patients of a replication-defective avipox recombinant vaccine that expresses human carcinoembryonic antigen. J. Clin. Oncol. 17, 332–337 (1999).
   PubMed Web of Science ®Google Scholar
• Foon KA, Chakraborty M, John WJ, Sherratt A, Kohler H, Bhattacharya-Chatterjee M. Immune response to the carcinoembryonic antigen in patients treated with an anti-idiotype antibody vaccine. J. Clin. Invest. 96(1), 334–342 (1995).
   PubMed Web of Science ®Google Scholar
• Marshall JL, Hoyer RJ, Toomey MA et al. Phase I study in advanced cancer patients of a diversified prime and boost vaccination protocol using recombinant vaccinia virus and recombinant nonreplicating avipox virus to elicit anticarcinoembryonic antigen immune responses. J. Clin. Oncol. 18, 3964–3973 (2000).
   PubMed Web of Science ®Google Scholar
• von Mehren M, Arlen P, Tsang KY et al. Pilot study of a dual gene recombinant avipox vaccine containing both carcinoembryonic antigen (CEA) and B7.1 transgenes in patients with recurrent CEA-expressing adenocarcinomas. Clin. Cancer Res. 6(6), 2219–2228 (2000).
   PubMed Web of Science ®Google Scholar
• Horig H, Lee DS, Conkright W et al. B7.1 costimulation enhances the response of a recombinant canarypoxvirus (ALVAC) vaccine expressing human carcinoembryonic antigen (CEA). Cancer Immunol. Immunother. 49, 504–514 (2000).
   PubMed Web of Science ®Google Scholar
• Marshall JL, Gulley JL, Arlen PM et al. Phase I study of sequential vaccinations with fowlpox-CEA (6D)-TRICOM alone and sequentially with vaccinia-CEA (6D)-TRICOM, with and without granulocyte-macrophage colony-stimulating factor, in patients with carcinoembryonic antigen-expressing carcinomas. J. Clin. Oncol. 23(4) 720–731 (2005).
   PubMed Web of Science ®Google Scholar
• Schuetz TJ, Kaufman HL, Marshall J, Safran H. Extended survival in second-line pancreatic cancer after therapeutic vaccination. Proc. Am. Soc. Clin. Oncol. 23, S184 (2005).
   PubMed Web of Science ®Google Scholar
• Greenlee RT, Murray T, Bolden S et al. Cancer Statistics, 2000. CA Cancer J. Clin. 50, 7–33 (2000).
   PubMed Web of Science ®Google Scholar
• Rosenberg L. Pancreatic cancer: a review of emerging therapies. Drugs 59, 1071–1089 (2000).
   PubMed Web of Science ®Google Scholar